PA
ICPT

Perceptive Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Perceptive Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,000
Closed -$4.73M – 144
2014
Q2 		$4.73M Buy
+20,000
New +$5.27M 0.46% 44

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Perceptive Advisors's ICPT Position: Q1 2020 in Review

Perceptive Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 97,600 shares — an estimated $12.1M sold.

Perceptive Advisors first reported a position in ICPT in Q3 2017 and held it in 5 quarters. The position peaked at $12.1M in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Perceptive Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Perceptive Advisors sold 97,600 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $12.1M.
  • Perceptive Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
  • Perceptive Advisors's Intercept Pharmaceuticals, Inc. position peaked at $12.1M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.